<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Activating MET kinase rearrangements in melanoma and Spitz tumours.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Activating MET kinase rearrangements in melanoma and Spitz tumours." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f96b/4446791/fe48d7481b16/nihms-681531-f0005.jpg"/> </div> <div class="text-side"> <h1>Activating MET kinase rearrangements in melanoma and Spitz tumours.</h1> <p>ZKSCAN-1 MET is tumorigenic(a) Melan-a stably transduced with a ZKSCAN1-MET expression construct were injected into NOD/SCID/interleukin 2 receptor γ null mice (1.5 million cells, bilateral flank injections) with matched GFP transduced controls. All six injection sites with ZKSCAN1-MET expressing melan-a cells developed tumors within 5 weeks (black circles), whereas no tumors developed at the sites injected with GFP transduced controls (n=6) after 12 weeks (blue triangles). (b) Tumor formation 28 days after injection with ZKSCAN1-MET expressing melan-a cells. Scale bar, 0.5 cm. (c) Histopathology of ZKSCAN1-MET tumor (4x) demonstrates tumor cells diffusely within the skin and subcutaneous tissue. Scale bar, 500 μm. (d) At high power (20x) tumor cells have hyperchromatic and irregularly sized nuclei and mitoses are present. Scale bar, 10 μm. (e) Tumor cells have variable positivity for the kinase domain of MET (20x). Scale bar, 10 μm. (f) Tumor cells have variable levels of p-MET positivity (20x). Scale bar, 10 μm.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/26013381/" target="_blank">26013381</a></p><p>Type: Premalignant/Malignant, Category: Melanocytic</p>
</div> </div></div></body></html>